A Phase 1 Study of NM32-2668 (Anti-ROR1/Anti-CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors
Publications:
- A FIRST IN HUMAN PHASE 1 STUDY OF CG0070, A GM-CSF EXPRESSING ONCOLYTIC ADENOVIRUS, FOR THE TREATMENT OF NONMUSCLE INVASIVE BLADDER CANCER
- A FIRST-IN-HUMAN, PHASE 1, DOSE-ESCALATION STUDY OF DINACICLIB, A NOVEL CYCLIN-DEPENDENT KINASE INHIBITOR, ADMINISTERED WEEKLY IN SUBJECTS WITH ADVANCED MALIGNANCIE
NCT #
1-47,1-678
Condition(s)
Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Leiomyosarcoma, liposarcoma, Lung Cancer (NSCLC), Mesothelioma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Renal Cell Cancer, Skin Cancer/ Melanoma
Molecular Target(s)
ROR1
Drug Classification(s)
Molecular Targeted Therapy, Trispecific Antibodies
Agents(s)
NM32-2668
Phase(s)
I
Mechanism of Action
NM32-2668 is an anti-ROR1/Anti-CD3/Anti-HAS Tri-specific Antibody
Purpose
- How much of the study agent can be given with an acceptable level of side effects
- The effects of the study agent (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
- If research tests can be used in the future to predict who will benefit from NM32-2668
- How the study agent is acting on your body
- If your body develops any antibodies against the study agent which could reduce the amount of the study agent in your blood and the effects of the study agent on your disease
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.